

Coagadex® (coagulation Factor X [human]) - New and expanded indications

- On September 21, 2018, the <u>FDA approved</u> Bio Products Laboratory's <u>Coagadex (coagulation factor X [human])</u>, in adults and children with hereditary Factor X deficiency, for on-demand treatment and control of bleeding episodes, perioperative management of bleeding in patients with mild and moderate hereditary Factor X deficiency, and for routine prophylaxis to reduce the frequency of bleeding episodes.
 - The labeling was updated to remove age restrictions, expanded to include perioperative management of bleeding in patients with moderate hereditary Factor X deficiency, and updated to include a new use for routine prophylaxis.
 - Previously, Coagadex was approved for adults and children (aged 12 years and above) with hereditary Factor X deficiency for: (1) on-demand treatment and control of bleeding episodes and (2) perioperative management of bleeding in patients with mild hereditary Factor X deficiency.
- The new indication of Coagadex is supported by efficacy data from an open-label clinical trial with Coagadex use in routine prophylaxis of bleeding episodes in patients with hereditary Factor X deficiency. The study included 9 children aged < 12 years.
 - Investigators' assessment following 6 months of routine prophylaxis was rated excellent in all 9 patients (defined as 'no minor or major bleeds occurred during the study period' or 'lower frequency of bleeds than expected, given patient's medical/treatment history').
 - A total of 22 infusions were given to treat a bleed, equivalent to 2.1 bleeds per patient per year.
- The recommended initial dose of Coagadex for prophylaxis of bleeding episodes is 40 IU/kg twice weekly for children < 12 years and 25 IU/kg twice weekly for adults and adolescents ≥ 12 years of age.
- Refer to the Coagadex drug label for monitoring information and dosing for all other indications, including perioperative management of bleeding in patients with moderate hereditary Factor X deficiency.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.